Drugs / recombinant human Lecithin Cholesterol Acyl Transferase
recombinant human Lecithin Cholesterol Acyl Transferase
also known as
MEDI6012 · ACP501 · lecithin cholesterol acyltransferase · recombinant human LCAT · rhLCAT
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01554800 | Mar → Sep 2012 | atherosclerosis, coronary artery disorder | MedImmune LLC | Completed | No outcome recorded |
| Phase 23 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT03578809 | Jun 2018 → Jan 2021 | ST-elevation myocardial infarction | MedImmune LLC | Completed | Missed primary |
| Phase 2 | NCT03004638 | Jan → Nov 2017 | atherosclerosis | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT02601560 | Dec 2015 → Aug 2016 | coronary artery disorder | MedImmune LLC | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03773172 Comparator | Jan 2019 → Aug 2020 | cardiovascular disorder | Columbia University | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-08-20 | AstraZeneca | Results AstraZeneca is advancing understanding of cardio-renal-metabolic interconnectivity with new evidence at ESC 2018 astrazeneca.com ↗
Phase IIa results from the first collaboration between MedImmune and TIMI Study Group indicate the potential therapeutic benefit of MEDI6012, a lecithin-cholesterol acyltransferase (LCAT), for the treatment of atherosclerosis in patients having experienced the most serious type of heart attack |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-08-20 | AstraZeneca | AstraZeneca is advancing understanding of cardio-renal-metabolic interconnectivity with new evidence at ESC 2018 astrazeneca.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant human Lecithin Cholesterol Acyl Transferase | “This study is a phase 1, intravenous, open-label, single-dose escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ACP-501...” NCT01554800 ↗ |
| Known as | ACP501 | “MEDI6012 and ACP501 have the identical amino acid sequence and are therefore considered the same molecular entity.” NCT03773172 ↗ |
| Known as | lecithin cholesterol acyltransferase | “Background MEDI6012 is recombinant human lecithin cholesterol acyltransferase, the rate-limiting enzyme in reverse cholesterol transport.” PMID 34121413 ↗ Jun 2021 |
| Known as | MEDI6012 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03004638 ↗ |
| Known as | recombinant human LCAT | “METHODS AND RESULTS: A phase 1b, open-label, single-dose escalation study was conducted to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of recombinant...” PMID 26628614 ↗ Dec 2015 |
| Known as | rhLCAT | “This study is a phase 1, intravenous, open-label, single-dose escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ACP-501...” NCT01554800 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human LCAT (ACP-501)” PMID 26628614 ↗ Dec 2015 |
| Route | Intravenous | “single intravenous infusion” PMID 26628614 ↗ Dec 2015 |